GlaxoSmithKline’s COPD drug Anoro receives European green light

Your Health Matters

The GlaxoSmithKline building is pictured in Hounslow, west LondonAnoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday. It is expected to generate sales of more than $2 billion a year by 2018, according to the average estimate of six analysts polled by Thomson Reuters.

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave